Sleep problems are one of the most common non-motor symptoms of Parkinson's disease (PD). The Parkinson's disease Sleep Scale 2 nd version (PDSS-2) was published in 2011 showing satisfactory clinimetric results. We performed an independent testing of the scale adding further information on its clinimetric properties.
INTRODUCTION
Recently the non-motor symptoms (NMS) of Parkinson's disease (PD) have been increasingly recognized as major burden of quality of life 1, 2 . Among the NMS, sleep-related problems are one of the most important and troublesome. Therefore, screening for sleep-problems and measuring their severity is of great clinical importance. However, sleep-related problems are certainly multidimensional. For example, sleep-disturbances in PD might equally be due to PD-related problems (e.g. troublesome nighttime OFF symptoms, hallucinations, rapid eye movements sleep behavioral disorder -RBD, or restless legs syndrome -RLS) and other issues not specific for PD (e.g. arousals caused by sleep apnea syndrome or nocturia).
Based on the systematic review and evaluation of sleep-related rating scales by the Movement Disorders Society Task Force 3 , only a few scales were found to be appropriate for the PD population.
Although the original Parkinson's Disease Sleep Scale (PDSS) 4 was recommended by the MDS Task Force, they identified some weaknesses of the scale including the inability to specifically identify and measure sleep apnea, RBD and RLS problems. To overcome these disadvantages, a new scale, the Parkinson's Disease Sleep Scale 2 nd version (PDSS-2), was developed and published in 2011 5 . It is composed of 15 items evaluating three domains. Each item has a 5 point Likert-type scale ranging from 0: "Never" to 4: "Very often" (except for item 1 which is reversed). Each domain consists of clusters of five questions (Motor symptoms at night: 4, 5, 6, 12 and 13; PD symptoms at night: 7, 9-11 and 15; and Disturbed sleep: 1-3, 8 and 14) 5 . Symptoms on each domain can be scored in the range of 0-20 points; whereas, the sum of the 15 responses gives the total score of PDSS-2 with the maximum value of 60 points and higher scores meaning more nocturnal disturbance.
The PDSS-2 scale was validated on 113 PD patients in three centers in three different countries (United Kingdom, Germany and Austria). Clinimetric properties of the scale were confirmed by factor analysis, internal consistency, test-retest reliability, convergent and discriminative validity, and precision analyses. Based on their findings, the authors stated that PDSS-2 was a reliable, valid, precise and potentially treatment-responsive tool for measuring sleep problems in PD 5 . Therefore, the usage of PDSS-2 is recommended for screening and grading the severity of sleep problems in PD 6 . Additionally, the clinical usefulness of PDSS-2 was also demonstrated in many clinical studies. First, PDSS-2 was utilized in a doubleblind, placebo-controlled trial assessing the efficacy of rotigotine on nocturnal disabilities 7 . Recently the responsiveness of PDSS-2 was also demonstrated after various therapeutic interventions including levodopa/carbidopa intestinal gel 8 infusion and bilateral subthalamic deep brain stimulation 9 .
The objective of the present study was to perform an independent and intercultural validation of the PDSS-2 following the principles of the Classical Test Theory 10 .
MATERIALS AND METHODS

Patients
In this nation-wide cross-sectional multicenter study 537 consecutive patients fulfilling the UK Brain Bank criteria for PD were enrolled in 9 centers. Each subject gave written consent in accordance with the ethical approval of National Ethical Committee (184/2013. 14437/2013/EKU). Each patient was examined by neurologists specialized in movement disorders. Portion of these patients (357/537) participated in the program of cultural adaptation and validation of the Movement Disorders Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) 11 and Unified Dyskinesia Rating Scale 12 into Hungarian.
Patients with major neurocognitive decline were excluded from the study. Presence of dementia was defined as either having scores ≤125 points on Mattis Dementia Rating Scale (n=427) 13 and/or scores ≤22 points on Montreal Cognitive Assessment (n=537) [14] [15] [16] . Patients received their usual antiparkinsonian and other medication during the assessments. Subsequently, levodopa equivalent dosage calculations were performed 17 .
Obtained rating scales
Severity of sleep problems were globally characterized by a Patients' Global Impression Scale (PGI) adjusted for sleep disturbances: no sleep problems, borderline/mild problems, moderate problems, marked problems and severe problems.
The PDSS-2 was translated according to approved translation standards into Hungarian (NK and BF) and back-translated into English (PA). Subsequently the original English and the back-translated English versions were compared 18 .
Besides PDSS-2, socio-demographic and PD-related data, the Hungarian validated versions of MDS-UPDRS 11 , PDQ-39 19 and Epworth Sleepiness Scales (ESS) 18, 20 were obtained. As being part of the MDS-UPDRS, the original Hoehn-Yahr Scale (HYS) was also taken to detect the overall severity of PD 21 . Because data from these scales were categorical, non-parametric tests were applied. Data were summarized at University of Pécs (by KH and NK).
Descriptive data analysis
As the items of most applied scales were ordinal variables, medians with interquartile range (IR, 25 th -75 th percentiles) were calculated. Because a score of 0 means symptom-free condition, the prevalence of each item was based on the portion of subjects having the score >0 point on that particular item. For variables following the normal distribution (e.g. age, disease-duration), medians ± standard deviations (SD) were also calculated.
Data quality was defined as the proportion of computable data. The criterion for acceptable amount of missing data is <10% 22 . For acceptability the floor and ceiling effect should be kept <15% 23 and the skewness should range between -1 and +1 24 .
Factor analysis
Before the structure of the scale was explored by a factor analysis, the value of Kayser-Meyer-Olkin measure of sampling accuracy (KMO) was calculated. A KMO>0.60 is a minimum requirement; whereas, KMOs >0.90 are considered as excellent for factor analysis. We accepted only those factors having an eigenvalue >1 and a Scree test for factor analysis.
Reliability
In the clinimetrics, reliability is the overall consistency of a measure. A measure is said to have a high reliability if it produces similar results under consistent conditions 10 . In our study the internal consistency was evaluated by three approaches:  Cronbach's α (should be >0.70) 25  corrected item-total correlation (should be >0.30 for each item)
 item homogeneity coefficient (should be >0.30).
Because the test-retest reliability of the Hungarian PDSS-2 was previously reported elsewhere 26 , in this independent validation project we did not include the assessment of the test-retest properties of the scale.
Validity
Validity of an assessment is the degree to which it measures what it is supposed to measure. Therefore, it corresponds to how a measurement is well-founded and accurately describes the real world 10 .
In our study the construct validity was evaluated by three different methods:
 Convergent validity: Convergent validity refers to the degree to which a measure is correlated with other measures that it is theoretically predicted to correlate with 10 . The total score and the subscores of PDSS-2 were compared to the PGI, Non-Motor Symptoms Scale (including the Sleep Subscale), MDS-UPDRS and PDQ-39. For correlation, Spearman's rank correlation coefficients were calculated. The values of correlation coefficients can indicate weak (0-0.299), moderate (0.300-0.599) and high (0.600-1.000) association 27 .
 Internal validity. The correlation between the domains (subscales) should not be too low (rS<0.300) or too high (rS>0.700) either 28 .
 Discriminative validity. Discriminative validity tests whether concepts or measurements that are supposed to be unrelated are, in fact, unrelated 10 . It is well-known, that the prevalence and/or the severity of sleep-problems depend on age, sex 29, 30 , education level, diseaseduration and Hoehn-Yahr Staging 31 . Therefore, we tested the discriminative validity of PDSS-2 against these factors.
Precision
Precision of the PDSS-2 was estimated by standard error of measurement (SEM), where the value of SEM should be less than the half of the standard deviation.
Receiver operating characteristic (ROC) curve
In order to establish a cut-off value for the total score of PDSS-2, which can reliably differentiate the presence or absence of sleep-related problems, we applied ROC analysis. Patients were categorized by the PGI value (no problems at all vs. presence of sleep-disturbances with any degree). This categorization served as the state variable and PDSS-2 total score as the test variable. The best cut-off value was estimated as the point on the ROC curve closest to the point of (0,1). It was calculated as the minimum value of the square root of (1-sensitivity) 2 +(1-specificity) 2 . Besides, area under the curve, specificity, sensitivity, positive and negative predictive values (PPV and NPV, respectively) and diagnostic accuracy were calculated for the best cut-off value. Subsequently, we also tried to calculate a threshold value for discriminating marked sleep problems from mild-moderate sleep-problems based on the PGI value (having marked and severe sleep problems vs. having mild and moderate sleep disturbances).
Statistical analysis
All statistical analyses were carried out using IBM SPSS software package (version 21, IBM Inc., Chicago, USA). Statistical significance level was set to 5%. Because the SPSS Suite did not have built-in functions for calculating positive and negative predictive values, we utilized the syntax available on the IBM website (http://www-01.ibm.com/support/docview.wss?uid=swg21483380, assessed on Jan 15, 2013).
RESULTS
Demographic and PD-related clinical data
The subject population consisted of 537 non-demented PD patients. The clinical characteristics are demonstrated in Table 1 .
Descriptive measurements
Based on the PGI scale, 161 patients (30.0%) did not report any sleep problems; whereas, 114 patients (21.3%) had mild/borderline, 96 (17.9%) had moderate, 133 (24.8%) had marked and 33 (6.0%) had severe sleep problems ( Table 1 ).
Only 9 patients had a total score of 0 on PDSS-2. The prevalence of PDSS-2 items varied differently:
Item 7 (hallucinations) had the lowest prevalence (16.9%), whereas, item 8 (nocturia) had the highest (88.6%, Table 2 ). Frequency of scores, median, 25 th and 75 th percentile values are shown in Table 2 . Data quality was excellent for all PDSS-2 items (Table 3 )
Factor analysis
The KMO value was sufficiently high (0.884) to enable a factor analysis. The Scree-test supported a one-or a three-factor solution explaining 28.9% and 38.9% of the variance, respectively. Using Principal Component Analysis extraction method with Varimax rotation, we identified almost the same factor structure as it was originally described ( Table 4) . Only item 8 "Nocturia" had somewhat different profile: It had almost identical loading for both "PD symptoms at night" and "Disturbed sleep" domains.
Reliability analysis
The value of Cronbach's α for the domains of the PDSS-2 varied between 0.715-0.748; whereas, for the total score it was 0.863 ( Table 3 ). All the items reached the 0.30 threshold value for item-total correlation ( Table 3) . Item homogeneity index values were acceptable for all subdomains and the total score of PDSS-2. Table 5 Table 5 ). As far as the discriminative properties were considered, all the domains and the total score significantly differed between males and females and among various age groups, education-levels, disease-duration, Hoehn-Yahr Staging and PGI groups (p<0.01 and p<0.001, Kruskal-Wallis tests).
Validity and precision
The precision were acceptable for both the domains and the total score of PDSS-2 ( Table 3) 
ROC analysis
The cut-off value which best discriminated the presence of sleep disturbances from the absence was 10.5 points; therefore a total score ≥11 points on PDSS-2 may suggest the presence of clinically meaningful sleep-problems in PD. This cut-off value has sensitivity of 85.3%, specificity of 60.8%, PPV of 83.6%, NPV of 64.1% and diagnostic accuracy of 78.1%. The area under the curve was 0.810, whereas the ROC analysis yielded the statistical significance level (p<0.01).
The best cut-off value indicating the presence of marked sleep-problems was 19.5 points (specificity: 68.5%, sensitivity: 78.0%, PPV: 56.7%, NPV: 83.9% and diagnostic accuracy: 74.3%).
DISCUSSION
The aim of the present study was to develop the cross-cultural adaptation of the PDSS-2 and assess the fundamental clinimetric properties of the scale according to the principles of the Classical Test Theory.
Concerning the descriptive properties, the obtained data quality was excellent and skewness was satisfactory for all subdomains of the scale. The ceiling effect was also negligible for all the domains of the PDSS-2. While the "Motor symptoms" and "PD symptoms" subscales had relatively high, the "Disturbed sleep" subdomain and the total score of the PDSS-2 had acceptable floor-effect. Although the presence of a high floor or ceiling effect may be an indicator for poor acceptability or faulty content validity and may also negatively influence the reliability and sensitivity of the measurement, we suspect other issue in the background. Because many patients (n=161, 30% of the examined population) did not have clinically meaningful sleep-problems these moderately high floor-effect values (18.3% and 18.1%) might be due the characteristics of the studied sample and not attributable to the scale itself. This assumption is further supported by the fact that the whole PDSS-2 scale (the total score) had only a negligible floor effect (1.7%).
Based on the sufficiently high KMO value, the performed factor analysis revealed almost an identical factor structure reported in the original validation study of PDSS-2. We observed only one minor issue about item 8 called "Nocturia". This item had almost the same loadings for both "PD symptoms at night" and "Disturbed sleep" domains (0.310 and 0.316, respectively). Moreover, nocturia is one of the most frequent phenomenon in sleep disturbances associated with PD. It can be caused by both PD-related and PD-unrelated problems. In some cases the PD symptoms (especially in OFF states) can produce urgency and dysuria as well as nocturia. However, obesity, cardiac failure, sleep apnea are the most important unrelated issues capable of producing nocturia 32 . Therefore, it is not surprising that the "Nocturia" item might similarly load in the "PD symptoms at night" and "Disturbed sleep" domains of PD. In our opinion, this issue might be considered as only a minor change from the original factor structure.
Concerning the reliability of the scale, we obtained satisfactory results. The internal consistency of the PDSS-2 was acceptable with alpha indexes clearly exceeding the threshold value of 0.70. Total score reached an alpha value higher than 0.8 indicating its usefulness for individual comparisons. All items surpassed the threshold value of 0.30 for the item-correlations. Because the independent validation of reproducibility of PDSS-2 was reported elsewhere 26 , in this study we did not evaluate the test-retest validity of the scale. That study demonstrated sufficiently high values for both the Intra-class and Lin's Concordance Correlation Coefficients (0.782 and 0.799, respectively, for the total score of PDSS-2) indicating good reproducibility.
As assumed, the convergent validity between the PDSS-2 and other scales measuring similar constructs was satisfactory. The Spearman's rank correlation coefficients indicated high correlation with the PGI, the Sleep section of NMSS, the total score of NMSS and the Non-motor Experiences of MDS-UPDS.
Similarly to the original validation study 5 , we also observed high correlation between PDSS-2 and PDQ-39 Summary Index, an indicator of the contribution of sleep problems to impaired health-related quality of life. Similarly to the original PDSS-2 validation study, we also revealed low correlation between the PDSS-2 (nocturnal problems) with ESS (daytime sleepiness) and neurocognitive tests.
PDSS-2 showed satisfactory discriminative ability to differentiate based on gender, and between patients grouped according to age decades, education-levels, PD duration and HYS. ( Table 6 ).
The PDSS-2 subscales also correlated with each other to a moderate/high level into the standard limits for internal validity (rS=0.3-0.7, Table 5 ). The standard error of measurement values were suggestive of a high precision for all components of the scale.
As far as the authors are aware of, only a single study is published on the cut-off value for PDSS-2 differentiating clinically meaningful sleep disturbances. Suzuki and coworkers reported an optimal PDSS-2 cut-off to be 14 or 15 points for identifying poor sleepers using Pittsburgh Sleep Quality Index >5 points 33 .
Based on our results, total scores higher than 10 points are indicative of sleep disturbances and identify subjects whose problems need further investigation. This discrepancy may be due to the different cultural background of the study population (Japanese vs. Hungarian), number of included patients (146 vs. 537) and different anchors applied (Pittsburgh Sleep Quality Index vs. PGI). Because sleep habits are considerably variable among different cultures, we suggest that distinct cut-off scores should be validated for particular PD populations.
We also calculated a threshold value for indicating the presence of marked sleep-problems. This additional cut-off value may be clinically useful for categorizing the degree of sleep-disturbances.
The strength of our study is its multicenter nature involving a large population of non-demented PD patients. However, we also have to admit some weaknesses. A major limitation of the current validation study is the lack of polysomnography assessment (which should be regarded as better concurrent validity criterion). Polysomnographic data could provide interesting additional information; however, these data are not mandatory for performing a cross-cultural validation of an existent scale and determining the cutoff score. Another limitation of our study is the exclusion of demented patients even though that cognitively impaired PD subjects may have apparently more disturbances with sleep quality. We decided to exclude demented patients form this study, because in our opinion severe dementia might interfere with the reliability of PDSS-2 data. We assumed that severely demented patients (<125 points on Mattis Dementia Rating Scale) might not fill the PDSS-2 forms as accurately as it should be, which might have a negative impact on data quality. To compensate this weakness, we tried to evaluate any possible relationship between the scores on neurocognitive tests and PDSS-2. However, we could not identify clinically meaningful correlation between the scores of MDRS and PDSS-2 (Table 5) .
CONCLUSIONS
Patient reported outcomes and self-completed questionnaires are widely used for patient assessment, follow-up and making clinical decisions in both clinical practice and research. Validation of adapted scales is important to assure the usefulness of the instrument in the setting in which it will be applied. The most important indicators for the quality of a scale are the reliability, validity and responsiveness. Because the replication of outcomes is a highly desirable scientific need, the independent validation of patient reported outcomes is essential to confirm or reject the findings obtained by the developers of the scale. Our results demonstrate that the fundamental clinimetric properties of the Hungarian validated version of PDSS-2 are satisfactory and confirm those of the original study 5 . Presence of dementia was defined as having scores ≤125 points on Mattis Dementia Rating Scale and/or scores ≤22 points on Montreal Cognitive Assessment. Extraction Method: Principal Component Analysis. The items belonging to individual factors are highlighted by gray background. 
